5 Best Cancer Stocks To Buy Now

Page 5 of 5

1. Johnson & Johnson (NYSE:JNJ

Number of Hedge Fund Holders: 88

Johnson & Johnson (NYSE:JNJ) operates a strong cancer pharmaceutical segment and it tops our list of 10 best cancer stocks to buy now. In the second quarter of 2021, the company’s revenue in the pharmaceutical segment grew 13.8% year over year to $12.9 billion. One of the revenue drivers in the quarter was Johnson & Johnson’s (NYSE:JNJ) leading cancer medicine, Darzalex.

On October 20, Raymond James analyst Jayson Bedford maintained an Outperform rating on Johnson & Johnson (NYSE:JNJ). The analyst set a price target of $178 per share. The stock gained 13% in the past twelve months.

Fundsmith LLP is the biggest stakeholder of the company as of the second quarter, with a $1.18 billion stake. Overall, 88 funds of the 873 elite funds tracked by Insider Monkey reported owning stakes in Johnson & Johnson (NYSE:JNJ) at the end of June 2021.

In the Q2 2021 investor letter of Distillate Capital, the fund mentioned Johnson & Johnson (NYSE:JNJ) and discussed its stance on the firm. Here is what the fund said:

“The largest additions in the rebalance, Johnson & Johnson was around 50 and 40 basis points incrementally. J&J underperformed in the quarter while its normalized free cash flows held steady and so its position size was topped off to match the stable cash flows.”

You can also take a peek at the 11 Best High Dividend Stocks Under $50 and Mark Cuban Stock Portfolio: 10 Stocks To Consider.

Follow Insider Monkey on Twitter

Page 5 of 5